Afluria Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Afluria market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the rising incidence of influenza, the growing geriatric population, higher healthcare expenditure, increased awareness of vaccine safety, and the expansion of public health campaigns.

The projected growth during the forecast period can be attributed to increasing government support, a growing focus on preventative healthcare, efforts to mitigate vaccine hesitancy, the expansion of healthcare systems, and rising income levels in emerging economies. Key trends expected in this period include the integration of telehealth for vaccination consultations, investments in cold chain logistics, the use of artificial intelligence in vaccine development, government incentives for vaccination, and collaborations with technology companies.

The increasing prevalence of influenza is expected to drive the growth of the afluria market in the coming years. Influenza, commonly known as the flu, is a contagious respiratory disease caused by influenza viruses, which can lead to mild to severe illness. Symptoms typically include fever, cough, sore throat, body aches, and fatigue. The rising prevalence of influenza can be attributed to several factors, including greater public awareness of the disease, higher incidence rates due to viral mutations, and increased demand for vaccinations, particularly among vulnerable populations such as the elderly. Afluria is a vaccine used to prevent influenza by stimulating the immune system to produce antibodies against the flu virus. For example, the UK Health Security Agency reported in November 2024 that influenza positivity rates rose to 2.3% in week 41, up from 2% the previous week. The highest rates were observed in individuals aged 5 to 14 years, with a rate of 5.1%. This growing prevalence of influenza is driving the demand for vaccines like afluria.

The expanding geriatric population is expected to contribute significantly to the growth of the afluria market. The geriatric population, defined as individuals aged 65 and older, has unique health needs due to the challenges associated with aging. This demographic is increasing as a result of declining fertility rates and longer life expectancy, leading to a higher proportion of older adults in the overall population. Older individuals are particularly vulnerable to severe illness and mortality from influenza, making effective vaccination strategies such as Afluria essential for protecting them and reducing flu-related health complications. For example, according to a July 2024 report from the House of Commons Library, the UK's population of individuals aged 65 and over was 12.7 million in 2022, accounting for 19% of the total population. This number is projected to rise to 22.1 million, or 27% of the population, by 2072. This increase in the geriatric population is driving demand for vaccines like afluria.

A key trend in the afluria market is the development of innovative solutions, such as nanoparticle-based vaccines, to enhance vaccine efficacy, stability, and targeted delivery. Nanoparticle-based vaccines use tiny particles, often in the nanometer range, to deliver antigens more effectively and improve immune responses. For example, in March 2024, Cadila Pharmaceuticals Ltd., an India-based pharmaceutical company, launched the Cadiflu Tetra Vaccine, an advanced quadrivalent influenza vaccine designed to prevent seasonal influenza. This vaccine targets four strains of the influenza virus, including subtypes A and B, offering broader protection against flu epidemics. It incorporates key proteins like hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) in a single formulation, resulting in a superior vaccine with a better safety profile compared to traditional vaccines.

Key player operating in the afluria market is CSL Seqirus.

North America was the largest region in the afluria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the afluria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Afluria is an inactivated influenza vaccine designed to protect against infections caused by specific strains of the influenza virus. Approved for individuals aged 6 months and older, it is administered via injection to stimulate the immune system to produce antibodies. Annual vaccination is recommended to maintain effective protection against seasonal flu outbreaks.

The primary types of afluria formulations are pre-filled syringes and multi-dose vials. Pre-filled syringes provide a single-dose option, ensuring accuracy and ease of use. These syringes are commonly utilized in outpatient clinics and pharmacies, helping to streamline vaccine administration. They also reduce the risk of contamination and support efficient immunization efforts. The primary clinical indication is influenza prevention. Afluria is distributed through hospitals, clinics, retail pharmacies, and government suppliers, and is used by pediatric, adult, and geriatric patients.

The afluria market research report is one of a series of new reports that provides afluria market statistics, including the afluria industry's global market size, regional shares, competitors with an afluria market share, detailed afluria market segments, market trends and opportunities, and any further data you may need to thrive in the afluria industry. This afluria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The afluria market consists of sales of afluria quadrivalent, and afluria trivalent. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.